,
4 min read
The IND application process in Nigeria applies to new chemical entities, biologics, vaccines, and investigational medicinal products, as well as major amendments such as new indications or delivery systems. Early confirmation of IND applicability helps sponsors avoid Regulatory delays.
In Nigeria, the process for an Investigational New Drug (IND) application is managed by the National Agency for Food and Drug Administration and Control (NAFDAC) and is referred to as a Clinical Trial Application (CTA).
Aligning early with NAFDAC clinical trial requirements ensures smoother interactions throughout the submission lifecycle.
Determine IND Requirement and Prepare for Submission
- Scope: IND is required for new drugs, vaccines, biologics, or significant amendments to existing products (like new uses or new drug delivery systems).
- Guidelines: Refer to the latest NAFDAC Clinical Trial Guidelines and updates on the official website: NAFDAC
- Manufacturers can request an optional pre-submission meeting with NAFDAC's Drug Evaluation and Research (DER) Directorate to discuss the study plan and clarify expectations (optional pre-submission consultation).
Profile Registration and Access to Application Systems
- The application, in triplicate with electronic copies, is submitted via the NAFDAC Electronic Clinical Trial Application Platform (NAFDAC-eCTAP) or to the nearest NAFDAC office.
- Access eCTAP: Register and log in to NAFDAC’s electronic Clinical Trial Application Platform (eCTAP) through their official website. This platform is used for profiling, submission, correspondence, and Regulatory tracking throughout the IND application process in Nigeria.
Assemble and Organize the IND Dossier
Compile in triplicate (plus two e-copies). Your dossier must include:
Administrative and Regulatory Documents
- Cover Letter outlining the IND request and trial details.
- Completed NAFDAC Clinical Trial Application Form.
- Valid Ethics Committee Approvals from all sites, including:
- Ethics Committee (EC) accreditation certificates from NHREC (National Health Research Ethics Committee).
- Minutes of EC meetings approving the protocol/consent.
- Investigator Agreements/Contracts between sponsor and investigator.
- Curriculum Vitae and proof of GCP training for all investigators.
- Insurance Certificate for clinical trial participants.
Technical Documents
- Study Protocol (scientific rationale, methodology, endpoints, safety, and statistical analysis plan).
- Informed Consent Forms (ICF) and Patient Information Leaflets (PIL), ensuring clarity and compliance with Nigerian language requirements if required.
- Evidence of ethical committee approval or a copy of the letter submitted for review.
- Investigator’s Brochure/Package Insert with all available preclinical and clinical data.
- Evidence of business registration (for the local agent, in case of foreign sponsors)
- Product Dossier:
- Chemistry, Manufacturing, and Controls (CMC) information.
- Complete documentation for the Investigational Medicinal Product (IMP): quality, stability, storage, and labeling.
- Previous Regulatory and Scientific Authorizations:
- Prior IND, NDA, or similar authorizations (if applicable).
- Summary of non-clinical and clinical data supporting the trial.
Site and GMP Documents
- GMP Certificate for the manufacturer of the IMP (authenticated for imports).
- Site Master File for manufacturing/storage facilities.
- Import Permits: If importing investigational products, an application for NAFDAC import permit is required.
Robust documentation is essential for meeting clinical trial approval Nigeria standards and minimizing Regulatory queries.
Submission & Fee Payment
- Portal Submission: Upload the application and all dossier documents onto eCTAP. Submit physical copies as requested.
- Regulatory Fee: Upon successful pre-screening, generate invoice, pay all applicable NAFDAC review/inspection fees via the official process, and upload payment receipts.
NAFDAC Evaluation, Ethics Review, and Communication
- Processing: NAFDAC reviews the application, requests clarifications as needed and may conduct parallel or sequential review with institutional ECs.
- Ethics Review: NAFDAC authorization is only given after independent Ethics Committee approval. Both Regulatory and ethical approvals must be secured.
- Scientific Advisory Meetings: Sponsors may be invited to meetings or presentations for clarification and justification.
- Communication: All correspondence and requests for additional documents are handled through the eCTAP portal.
- NAFDAC conducts a scientific review to assess the safety, quality, and efficacy of the proposed trial and the ethical clearance from the relevant ethics committee (institutional or national, depending on the number of trial centers).
Facility Inspection & Product Release
- GCP/GMP Site Inspection: NAFDAC may inspect the clinical trial and manufacturing sites to confirm compliance.
- Integrity Checks: Review of the IMP supply chain, labeling, storage, and handling.
- Import Permit and Product Release: On-site and port inspections occur for imported IMPs and support materials before clearance for clinical use.
Trial Conduct, Reporting, and Compliance
- Trial Initiation: Begin clinical trial ONLY after official written NAFDAC and EC approvals.
- Ongoing Obligations:
- Report Serious Adverse Events (SAEs), protocol deviations, trial amendments, and significant findings to both NAFDAC and EC.
- Submit periodic progress and final reports in line with NAFDAC’s requirements.
- Maintain trial master file and detailed records for audit.
- All trials must also be registered on the Pan African Clinical Trial Registry (PACTR)
- Post-Trial:
- Submit final report and request for trial closure.
- Ensure archiving and possible publication/data disclosure as mandated.
Additional Notes & Best Practices
- Align documentation to ICH-GCP and WHO standards.
- Maintain updated contact points for all submissions/correspondence.
- Systematically update NAFDAC should there be any Regulatory changes (e.g., variations in investigators, sites, or product formulation).
Summary
| Step | Stage Name | Key Focus | What This Step Involves |
| 1 | Determine IND Requirement & Preparation | Applicability & Planning | Confirm whether an IND is required for new drugs, biologics, vaccines, or major product changes. Early alignment with NAFDAC Clinical Trial Requirements helps prevent delays and rework. |
| 2 | Profile Registration & System Access | Regulatory Onboarding | Register on NAFDAC’s eCTAP platform to enable profiling, application submission, Regulatory correspondence, and lifecycle tracking of the IND application. |
| 3 | Assemble & Organize IND Dossier | Documentation Readiness | Compile administrative, ethical, technical, CMC, GMP, and site-related documents, including EC approvals, investigator credentials, IMP details, and insurance certificates. |
| 4 | Submission & Fee Payment | Formal Filing | Upload the complete IND dossier via eCTAP, submit physical copies if required, generate invoices, and complete all applicable NAFDAC review and inspection fee payments. |
| 5 | NAFDAC Evaluation & Ethics Review | Regulatory & Ethical Assessment | NAFDAC conducts scientific and Regulatory review alongside Ethics Committee evaluation. Queries, clarifications, and advisory meetings may occur during this phase. |
| 6 | Facility Inspection & Product Release | Compliance Verification | NAFDAC may conduct GCP/GMP inspections of clinical trial sites and manufacturing facilities. Import permits and IMP release are granted after successful verification. |
| 7 | Trial Conduct, Reporting & Compliance | Ongoing Oversight | Clinical trials may begin only after written approvals. Sponsors must report SAEs, amendments, deviations, and submit periodic and final reports as part of Clinical Trial Approval Nigeria obligations. |
| 8 | Additional Notes & Best Practices | Strategic Compliance | Maintain alignment with ICH-GCP and WHO standards, keep Regulatory contacts updated, and notify NAFDAC promptly of any changes to trial sites, investigators, or product details. |
Conclusion
The IND application process in Nigeria requires careful Regulatory planning, precise documentation, and strict adherence to NAFDAC and ethics committee requirements.
With evolving clinical trial expectations and increased Regulatory scrutiny, having the right expertise is essential Freyr supports sponsors at every stage of the IND lifecycle, from dossier preparation and submissions to inspections, approvals, and ongoing Regulatory compliance in Nigeria.
